Entropy Neurodynamics (ASX:ENP) said its TRP-8802 drug candidate showed a 75% response rate in a phase 2a clinical study for the treatment of irritable bowel syndrome, according to a Monday filing with the Australian bourse.

The results mark the "strongest clinical signal ever reported" in irritable bowel syndrome drug development and represent a treatment breakthrough compared with current therapies that register response rates of 17% to 44%, the company said.

The study analyzed two doses of TRP-8802 oral psilocybin alongside structured psychotherapy in 12 patients who had earlier failed multiple standard treatments, with the data indicating that the therapy candidate is targeting root-cause neurobiological pathways instead of just masking the chronic disorder's symptoms, Entropy said.

TRP-8802's safety profile was consistent with expectations for psychedelic‑assisted therapy, and the one serious adverse event that was recorded was resolved with clinical support, per the filing.

The company said it is in a strong position for partnering negotiations, larger trials, and grant funding opportunities, with a clear development pathway focused on the US, where patients spend more than $60 billion per year on treatments for the disease.

Entropy Neurodynamics shares gained 3% in recent Monday trade.